Sangart, Inc.

Phase 2 clinical trial for hemoglobin-based blood alternative Hemospan initiated

Published in Law and Health Weekly, August 20th, 2005

Sangart, Inc., a biopharmaceutical company developing oxygen transport agents, announced the initiation of a phase 2 clinical trial involving Hemospan (MP4), a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions.

This study, involving 40 patients, will be conducted at the Johns Hopkins University School of Medicine in Baltimore.

Sangart's approach to the development of oxygen transport agents employs technology that is the result of more than a decade of peer-reviewed research into the mechanism of oxygen transport by cell-free hemoglobin. Preclinical and clinical studies indicate that Hemospan is free of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-08-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry